- Home
- BOLD vs ALXO Comparison
BOLD vs ALXO Comparison
Compare BOLD & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- ALXO
- Stock Information
- Founded
- BOLD 2018
- ALXO 2015
- Country
- BOLD United States
- ALXO United States
- Employees
- BOLD N/A
- ALXO N/A
- Industry
- BOLD
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- ALXO Health Care
- Exchange
- BOLD Nasdaq
- ALXO Nasdaq
- Market Cap
- BOLD 30.3M
- ALXO 24.0M
- IPO Year
- BOLD 2024
- ALXO 2020
- Fundamental
- Price
- BOLD $1.13
- ALXO $0.56
- Analyst Decision
- BOLD Buy
- ALXO Strong Buy
- Analyst Count
- BOLD 3
- ALXO 6
- Target Price
- BOLD $4.00
- ALXO $3.30
- AVG Volume (30 Days)
- BOLD 79.0K
- ALXO 456.6K
- Earning Date
- BOLD 05-09-2025
- ALXO 05-08-2025
- Dividend Yield
- BOLD N/A
- ALXO N/A
- EPS Growth
- BOLD N/A
- ALXO N/A
- EPS
- BOLD N/A
- ALXO N/A
- Revenue
- BOLD N/A
- ALXO N/A
- Revenue This Year
- BOLD N/A
- ALXO N/A
- Revenue Next Year
- BOLD N/A
- ALXO N/A
- P/E Ratio
- BOLD N/A
- ALXO N/A
- Revenue Growth
- BOLD N/A
- ALXO N/A
- 52 Week Low
- BOLD $1.06
- ALXO $0.41
- 52 Week High
- BOLD $10.13
- ALXO $10.97
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- ALXO 59.08
- Support Level
- BOLD N/A
- ALXO $0.44
- Resistance Level
- BOLD N/A
- ALXO $0.48
- Average True Range (ATR)
- BOLD 0.00
- ALXO 0.05
- MACD
- BOLD 0.00
- ALXO 0.02
- Stochastic Oscillator
- BOLD 0.00
- ALXO 99.16
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.